Development of Fusogenic Immunomodulatory Macrophage-Mimicking Nanocarriers for Targeted Delivery to Inflamed Tissue (NANO-MAC)

Development of Fusogenic Immunomodulatory Macrophage-Mimicking Nanocarriers for Targeted Delivery to Inflamed Tissue

In this project, we propose to develop innovative macrophage-mimicking nanocarriers (MMCs) with fusogenic properties (FMMCs) for the targeted delivery of dexamethasone to inflammation sites, particularly for treating Inflammatory Bowel Disease (IBD). These nanocarriers, designed to mimic the natural targeting abilities of macrophages, aim to enhance therapeutic efficacy and reduce systemic side effects. To achieve this, we will first synthesize and optimize MMCs, incorporating fusogenic properties to improve cellular uptake and drug delivery efficiency. These will then be evaluated for biocompatibility, cytotoxicity, and their ability to modulate immune responses. Finally, we will test the (F)MMCs in a sophisticated in vitro model mimicking the gut-immune interface to assess their performance in a disease-relevant environment.

The successful execution of this project will not only advance the field of nanomedicine but will also contribute to a better understanding of nanoparticle-cell interactions and their potential in immunomodulation, paving the way for more effective and safer therapies for chronic inflammatory diseases. Overall, this project will allow me to independently lead a 2-year research initiative, advancing my expertise in the field of nanomedicine and drug delivery systems, and positioning me as a mature and independent researcher capable of contributing to the development of innovative therapies for chronic inflammatory diseases.